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Abstract
Objectives: Multiplemyeloma (MM) is amalignant plasma
cell neoplasm, requiring the integration of clinical exami-
nation, laboratory and radiological investigations for
diagnosis. Detection and isotypic identification of the
monoclonal protein(s) and measurement of other relevant
biomarkers in serum and urine are pivotal analyses.
However, occasionally this approach fails to characterize
complex protein signatures. Here we describe the devel-
opment and application of next generation mass spec-
trometry (MS) techniques, and a novel adaptation of
immunofixation, to interrogate non-canonical monoclonal
immunoproteins.
Methods: Immunoprecipitation immunofixation (IP-IFE)
was performed on a SebiaHydrasys Scan2.Middle-downde
novo sequencing and native MS were performed with
multiple instruments (21T FT-ICR, Q Exactive HF, Orbitrap
Fusion Lumos, andOrbitrap Eclipse). Post-acquisition data
analysis was performed using Xcalibur Qual Browser,
ProSight Lite, and TDValidator.
Results: We adapted a novel variation of immunofixation
electrophoresis (IFE) with an antibody-specific immuno-
subtraction step, providing insight into the clonal signa-
ture of gamma-zone monoclonal immunoglobulin
(M-protein) species. We developed and applied advanced
mass spectrometric techniques such as middle-down de
novo sequencing to attain in-depth characterization of the
primary sequence of anM-protein. Quaternary structures of
M-proteins were elucidated by native MS, revealing a pre-
viously unprecedented non-covalently associated hetero-
tetrameric immunoglobulin.
Conclusions: Next generation proteomic solutions offer
great potential for characterizing complex protein struc-
tures and may eventually replace current electrophoretic
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approaches for the identification and quantification of
M-proteins. They can also contribute to greater under-
standing of MM pathogenesis, enabling classification of
patients into new subtypes, improved risk stratification
and the potential to inform decisions on future personal-
ized treatment modalities.
Keywords: immunofixation electrophoresis; multiple
myeloma; native mass spectrometry; top-down protein
sequencing; truncated heavy chains.
Introduction
Multiple myeloma (MM) is a hematological malignancy
characterized by the uncontrolled expansion of clonal
plasma cells that encode for a unique monoclonal immu-
noglobulin (M-protein) [1]. It is a clinically andmolecularly
heterogeneous disease [2] with a complex pathogenesis
which is almost always preceded by premalignant or more
indolent phases, namely monoclonal gammopathy of un-
determined significance (MGUS) or smouldering multiple
myeloma (SMM). The plasma cells typically secrete one or
more M-proteins which are detected in the serum and/or
urine using various electrophoretic and immunochemical
techniques.
The diagnosis, assessment and risk stratification of a
patient suspected of having MM requires an integrated,
multifaceted laboratory approach, integral to which is the
detection and isotypic identification of the M-protein, the
well-defined electrophoretic signature found in the ma-
jority of patients presenting with a plasma cell dyscrasia
(PCD). The M-protein and the serum free light chain (sFLC)
levels are both essential in the differential diagnosis and
stratification of MM, and are the most widely used bio-
markers for monitoring the course of the disease [3]. The
M-protein is isotyped by either immunofixation (IFE),
which is considered to be the gold standard, or by immu-
nosubtraction using capillary zone electrophoresis in
monoclonal gammopathies involving IgA, IgG, and IgM
and where the M-protein is both discrete and conspicuous.
However, the complete and unambiguous identification of
complex immunoprotein signatures cannot always be
achieved using these methods alone.
The increasing use of molecular investigations is ex-
pected to become a major contributor for predicting the
likelihood of rapid disease progression, responsiveness to
specific drug combinations, and monitoring for minimal
residual disease (MRD) [4]. For example, recent in-
vestigations performed at the Mayo Clinic and the National
High Magnetic Field Laboratory have explored alternative
strategies including the use of several next-generationmass
spectrometry (MS) techniques. In monoclonal gammo-
pathies such as MM and light-chain amyloidosis, top-down
and middle-down MS analyses have been used to isotype
heavy (HC) and light chains (LC) [5, 6], and to detect low
levels of monoclonal proteins from serum that may have
otherwise gone undetected [7, 8]. MS techniques have the
potential to augment or eventually replace electrophoretic
techniques, given their higher sensitivity and specificity.
Herein we describe our work in developing and
applying new analytical techniques which can be used to
more accurately and sensitively evaluate immunoproteins,
particularly non-canonical myeloma proteins. These
methods were developed in the context of an unusual
M-protein, for which the currently available repertoire of
protein based investigations was unable to resolve the
complex protein signature that was observed. In brief,
analysis by capillary electrophoresis revealed a triple
Figure 1: Capillary electrophoresis.
(A) Electrophoretogram of serum indicating the gamma zone triple
gammopathy at diagnosis (blue) and at terminal relapse (red). At
terminal relapse the IgG kappa (peak C) is absent, with ectopic
expression of non-canonical M-proteins (truncated gamma HC
dimer, peak A; 128 kDa hetero-tetramer, peak B).
(B) Electrophoretogram of terminal relapse sample (post BME
reduction) demonstrating the resolution of the truncated gamma HC
dimer and the truncated gamma HC’s from the 128 kDa hetero-
tetramer into a single peak(1) and the monoclonal free kappa LC’s
and non-covalently bound kappa LC’s into another peak(2).
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gammopathy in the gamma zone, which included two
truncated species (Figure 1). The relevant clinical details
and disease progression of the patient were previously
published as a case report [9], and a succinct summary is
provided in the Supplementary Material section of this
manuscript. We selected this challenging sample as an
example of an aberrant class ofmalignant immunoproteins
that potentially could enhance and expand the current
repertoire of immunoprotein analyses.
Firstly, we employed a novel adaptation of IFE which
required an antibody-specific immunosubtraction/immu-
noprecipitation step prior to IFE analysis (IP-IFE). This
strategy was adopted to interrogate the clonal signature of
the M-protein species present in the gamma zone. Sec-
ondly, we leveraged native top-down MS in a novel appli-
cation to eject subunits from an intact immunoglobulin,
providing insight into quaternary structure which com-
plemented the IP-IFE approach. Thirdly, we developed a
middle-down de novo sequencing strategy to reveal the
primary structure of the unusual immunoprotein complex.
On the basis of these studies and in conjunction with
routine immunochemical data,we demonstrated that these
techniques are effective for proposing conformational
structures for myeloma proteins. We also highlight limi-
tations of current methodologies, in contexts where both
canonical and non-canonical (truncated) M-proteins are
secreted by mutated plasma cells.
Materials and methods
Ethical approval
The research related to human patient samples has been complied
with all the relevant national regulations, institutional policies and in
accordance with the tenets of the Helsinki Declaration, and has been
approved by the authors’ Clinical Haematology Department. Informed
consent was obtained from the individual included in this study.
Immunoprecipitation immunofixation (IP-IFE)
The pre-IFE incubation step precipitates intact immunoglobulin and
free HC or LCs corresponding to the antibody added, or to which it is
bound. The subsequent IFE with each antibody which had been
precipitated demonstrates complete removal of that antibody.
Three 10 μL aliquots of a one in four dilution of the patients’
serum were mixed with 100 μL of Dynamic mask IFE antisera (Sebia)
which are optimally concentrated to facilitate the initial precipitation
step. A further 10 μL aliquot wasmixedwith standard Sebia IFE kappa
free antiserum, which had been concentrated by a factor of 1.5. A
control sample was also selected which contained an IgG kappa
M-protein, in the absence of monoclonal free LC’s. The antibody
treated samples were incubated for 48 h at 4 °C, centrifuged at
1,500 × g for 10 min and the supernatants decanted from the precip-
itated antigen-antibody complex.
The IFE was performed on the Sebia Hydrasys Scan 2. The
migration lanes of the separated proteins were overlaid with gamma,
kappa (free and bound), lambda (free and bound), and kappa free
antisera which resulted in precipitation of any corresponding antigen
present in the supernatant. After removal of the unprecipitated soluble
proteins the antigen-antibody complex trapped within the gel matrix
was stained with Acid Violet.
Sample preparation for mass spectrometry
Immunoglobulins were enriched from serum using a Melon Gel IgG
spin purification kit (Thermo Scientific), and enrichment was verified
by SDS-PAGE (Supplementary Material, Figure S1). Some samples
were reduced with TCEP/GdnCl. Digestion was performed with IdeS
protease (Promega), followed by reduction to produce LC, Fd, and Fc
subunits [10]. All samples were buffer exchanged in centrifugal filter
units prior to MS analysis. Samples for denaturing experiments were
exchanged into 5:95 acetonitrile:water containing 0.1% formic acid;
samples for native experiments were exchanged into 200 mM
ammonium acetate.
Mass spectrometry analysis
Intact mass measurements were acquired under denaturing condi-
tions using an Ultimate 3000 nanoLC (Thermo Scientific) fitted with a
polymeric monolithic RP-5H column (100 mm L, 0.5 mm i.d.) online
with FTMS (Q Exactive HF, Thermo Scientific). Intact mass analysis
under native conditions were performed by direct infusion with a
Nanospray Flex ion source (Thermo Scientific) attached to an Orbitrap
Eclipse Tribrid (Thermo Scientific), and subunit ejection was per-
formed by modifying the compensation voltage. For de novo
sequencing, the subunits resulting from IdeS digestionwere separated
by reverse phase chromatography, followed by targeted MS2 frag-
mentation. Additional acquisition parameters are described in the
Supplementary Material. Data analysis was performed using Xcalibur





The application of IP-IFE was utilized in order to probe for
the presence of free monoclonal gamma HC’s and to
determine if any antibody subtraction/precipitation
anomalies existed, which could help explain the uninter-
pretable immunosubtraction profile identified by capillary
electrophoresis. The inspection of the post IP-IFE separa-
tions confirmed the presence of several atypical M-proteins
(Figure 2). The absence of staining in the lambda lanes is
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due to the associated immune paresis affecting the poly-
clonal production of the threemain immunoglobulins, IgG,
IgA, and IgM.
The post gamma precipitation lanes revealed two free
monoclonal kappa LC bands. The non-detection of the free
monoclonal kappa LC’s with the kappa free antiserum is
due to their minute concentration and the lower avidity of
the kappa free antiserum. The post kappa (free and bound)
precipitation lanes revealed one small band in the IgG lane.
Since this bandwas also detected in the IgG lane of the post
lambda precipitation it most likely represents truncated
free gamma HC dimers. The post lambda precipitation
lanes revealed two bands with identical mobility to those
identified in the post gamma precipitation. However, there
was an additional large M-protein detected in the mid-
gamma region which immunofixed with gamma, kappa
(free and bound), and kappa free antisera.
On the basis of routine electrophoretic investigations it
may have been incorrectly concluded that this band was
composedof twoM-proteins (IgGkappaand freekappaLC’s)
having identical mobility. Although this bandwas absent in
the gamma and kappa (free and bound) precipitation lanes,
it reacted strongly with kappa free antiserum after precipi-
tation with lambda. However, free kappa was not identified
with this mobility after precipitation with gamma.
The post kappa free precipitation lanes are identical to
those obtained after kappa (free and bound) precipitation.
This IFE signature is not possible in the presence of an
intact covalently bound IgG kappa as demonstrated in the
control sample (Figure 2B). Only kappa (free and bound)
antiserum can precipitate the intact M-protein in the
control.
This very rare IP-IFE pattern posits the paradoxical
question of how a free LC antiserum can react with LC’s
which are not free. The series of antibody precipitations
outlined above are indicative of the presence of a non-
covalently bound immunoprotein consisting of both trun-
cated gamma HC’s and kappa LC’s. In this proposed
species the required target epitopes in the kappa LC’s are
exposed which will permit recognition by kappa free
antiserum.
When the IP-IFE procedure was repeated after sample
reduction with betamercaptoethanol the post gamma pre-
cipitation demonstrated that the two free kappa bands
Figure 2: Immunoprecipitation
immunofixation electrophoresis.
(A) Post IP-IFE (unreduced and post BME
reduction) with gamma, kappa, and lambda
antisera confirming the presence of free
gamma heavy chains which are not
precipitated with kappa or lambda and the
128 kDa species. (B) IP-IFE with kappa free
antiserum demonstrating the presence of
truncated gamma HC’s and the complete
removal of free kappa, and both heavy and
light chains found in the non-covalent
128 kDa species. The control sample
demonstrates that the intact IgG kappa
(150 kDa) cannot be subtracted by free
kappa.
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were reduced into one monomeric band (Figure 2A). The
post kappa precipitation was identical to the unreduced
samplewhereas the post lambda precipitation revealed the
presence of two bands, indicating that the most abundant
M-protein in the gamma region had been split into its HC
and LC components.
Structural insight from native mass
spectrometry
In order to further elucidate the structures indicated by
IP-IFE analysis, we applied native MS to investigate the
M-protein structures and connectivity within a native
buffer environment [11]. The intact native spectrum con-
tained one predominant charge state distribution, with
multiple proteoforms evident within each charge state
(Figure 3A). These deconvoluted to a cluster of intact
masses around 128 kDa (Table S2). Next, we applied a mild
dissociation voltage in the ion source region to check the
128 kDa species composition, which was hypothesized to
represent a pseudo-intact IgG structure containing trun-
cated HCs. We observed the gas-phase ejection of HC di-
mers and both LC monomers and dimers (Figure 3B). This
result implies that the HC and LC species are non-
covalently bound within the hetero-tetramer. By contrast,
canonical IgG’s would release no subunits in a low-energy
ejection experiment, since the HC and LCs are covalently
tethered by disulfide bonds. Our resultant hypothesis is
that the pseudo-intact species consists of a mixture of non-
covalent complexes including (A) one HC dimer bound to
one LC dimer and (B) one HC dimer bound to two LC
monomers.
Intact mass determination of monoclonal
immunoglobulins
High resolutionMS (HRMS) coupled to reverse phase liquid
chromatography (RPLC) was utilized to precisely deter-
mine the intact masses of the monoclonal immunopro-
teins. Under denaturing conditions, the mixture resolved
Figure 3: Native MS analysis of intact immunoproteins.
(A)MS1 spectrumof pseudo-intact IgG complex. (B)MS2 spectrumof
subunits ejected from pseudo-intact complex.
Figure 4: LCMSanalysis of intact immunoproteins under denaturing
conditions.
(A) The total ion chromatogram shows four distinct peaks (P1–4). (B)
FTMS spectra showing (P1) free LC’s, (P2) disulfide-bound LC dimers,
(P3) disulfide-bound HC dimers, and (P4) a pseudo-intact
heterotetramer.
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into four chromatographic peaks (Figure 4) whichmirrored
the species observed in the ejected native MS spectrum.
The deconvoluted masses of these species putatively
correlate to free LC’s (peak 1; 23705.1 & 23766.2 Da), an LC
homodimer (peak 2; 47175.2 Da), a truncated HC homo-
dimer (peak 3; 81013.0 Da & other glycoforms), and a
hetero-tetramer containing two LC’s and two truncated
HC’s (peak 4; 128187.6 Da & other glycoforms). Although
two unique LC monomers were detected in peak 1, neither
matched the presumed monomer mass corresponding to
peak 2. After reducing the intact sample, the chromatogram
simplified to two major species: an LC monomer
(23578.9 Da) and a truncated HC monomer (40515.6 Da).
These results support our hypothesis that the species
observed in peak 2 and peak 3 of the intact spectrum
correlate to LC and HC disulfide-bound homodimers, and
are consistent with the approximate MW estimation pro-
vided by SDS-PAGE (Supplementary Material, Figure S1).
In order to further localize the HC truncation, the
sample of ‘intact’ IgG was treated with IdeS protease,
which selectively cleaves the IgG HC at a site N-terminal to
the hinge region, thereby liberating the Fd and Fc subunits
(Figure 5). Treatment with IdeS protease was followed by
TCEP reduction. LCMS analysis demonstrated three chro-
matographic peaks, corresponding to the Fc, LC, and Fd
subunits. The deconvolutedmass of the LCwas 23578.9 Da,
the masses associated with the Fc were 25174.7 &
25336.7 Da – representing different glycoforms – and the
mass of the Fd was lower than hypothesized at 15334.5 Da.
These results localized the truncation to the Fd subunit.
De novo sequence analysis using middle-
down mass spectrometry
Having localized the truncation to the Fd subunit, we
sought to precisely characterize the sequence abnormal-
ities and to assess whether either the VH or CH1 region
remains intact in this species. Since the VH region amino
acid sequence is derived from VDJ recombination, stan-
dard database search approaches are incapable of
completely identifying this atypical species. Accordingly,
we applied a middle-down MS approach to deduce the Fd
sequence by de novo sequencing. Using RPLC in-line
with HRMS, the reduced Fd subunit was isolated
and subjected to multiple fragmentation techniques,
including collision-induced dissociation, higher-energy
collisional dissociation, electron-transfer dissociation,
electron-transfer/higher-energy collisional dissociation,
and ultraviolet photo dissociation. In combination, the
resulting fragmentation spectra provided high sequence
coverage of the Fd subunit (Figure 5). The theoretical
monoisotopic mass for the proposed sequence is
15334.3 Da (within 10 ppm error from observed mass), and
91% residue cleavages were observed (15 ppm tolerance).
This high resolution data can differentiate between
amino acids with very similar mass, such as glutamine
and lysine, however it cannot distinguish the isomeric
residues leucine and isoleucine. The only observed post-
translational modification is an N-terminal pyrogluta-
mate, which is expected when a sequence is initiated with
a glutamine residue [12].
The analysis of the obtained sequence reveals several
important features. It appears to contain an intact VH
region, which comprises framework regions consistent
with known VH patterns in the UniProt database. The
sequence includes the expected cysteine residues at po-
sitions 22 and 94 which form the VH structural loop. In
contrast, the CH1 region is almost completely absent;
there are only 15 connecting residues present between the
VH and the hinge region. The hinge region sequence
responsible for HC dimerization (CPPCPAPELLG) was
confirmed by fragmentation data, but crucially we did not
observe a cysteine residue at position 103 of the
CH1(hinge) which is requisite for disulfide bond forma-
tion between the Fd and the cysteine residue at position
Figure 5: (A) IdeS reaction products &
(B) graphical fragment map depicting the
resulting sequence from de novo sequencing
of the Fd subunit, with a combined sequence
coverage of 91% from multiple
fragmentation modes. Blue, red, and green
flags represent b/y, c/z, and a/x ions,
respectively. Leucine and isoleucine
residues could not be differentiated in this
analysis.
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106 of the kappa LC. These results provide a clear ratio-
nale for the lack of covalent bonds between LC and HCs,
contributing to the unusual fragmentation patterns
observed by native MS.
Discussion
Typical immunoglobulins have a hetero-tetrameric struc-
turewhich is assembledby the covalent linkage of twoHC’s
followed by successive attachment of two LC’s to the con-
stant region of the HC’s [13]. In the normal individual the
antigenic stimulus of B lineage cells can generate upwards
of 1016 possible unique sequences which constitute the
polyclonal immunoglobulin repertoire [13, 14]. However, in
MM, the plasma cell (end stage B cell) clone characteristi-
cally secretes a single complete immunoglobulin molecule
and/or free monoclonal LC’s, and is oftentimes accompa-
nied by concomitant immuneparesis.
The entry of immunoglobulins into the secretory
pathway is carefully regulated by quality control mecha-
nisms that ensure incompletely folded, misfolded, or
truncated proteins are retained, degraded and not
expressed in the peripheral blood circulation [15]. Com-
plete HC’s are therefore never secreted without an associ-
ated LC, but when deletions occur in the HC, particularly
involving the CH1 domain, the transportation of truncated
HC’s can be facilitated into the circulation [16]. Deletions,
insertions and point mutations are most likely acquired
during somatic hypermutation in the germinal center
B cells [17]. The CH1 region of the IgG antibody is an
intrinsically disordered domain which requires its cognate
partner, the CL domain, to fold the CH1 into the structure
observed in IgG antibodies [14, 18]. When the CH1 domain
is missing, LC’s can attach non-covalently to the CH2 or
CH3 domain of the HC [13].
The current standard immunochemical and electro-
phoretic techniques are satisfactory for the characteriza-
tion of structurally normal M-proteins but are inadequate
when non-canonical immunoglobulins are present. Simi-
larly, protein sequencing by a standard bottom-up prote-
omics approach can be successful in concert with
homology database searching, but this approach falls
short for novel antibody sequences which are not repre-
sented in databases. For the M-proteins described herein,
methodological limitations were observed with bottom-up
sequencing and with SDS-PAGE electrophoresis and
Western blot analysis of the unreduced sample, due to the
sequence novelty and structural instability of the 128 kDa
hetero-tetrameric species (data not shown). The presence
of Tris/glycine and SDS in the polyacrylamide gels resulted
in dissociation of non-covalent bonds, altered migration
and inaccurate MW determination of the pseudo-intact
IgG. In addition, the total IgG concentration was over-
estimated by immunoturbidimetry because the standard
curve is derived from an intact immunoglobulin calibrant.
Also, in the case of the 128 kDa species, the standard IFE
approach demonstrated co-incident staining for gamma,
kappa, and kappa free antisera which could have been
reported incorrectly as an intact IgG kappa M-protein co-
migrating alongside monoclonal free kappa LC’s. The
IP-IFE approach provided some degree of clarification, but
in doing so demonstrated anomalous antisera reactivity,
which suggested the presence of a truncated non-covalent
M-protein in the mid-gamma zone.
Amodification of this IP-IFE technique,which involves
initial precipitation with combined kappa and lambda
antisera [19], has recently been described in the context of
HC disease. This approach is appropriate in patients with
HC disease but would have failed to detect the 128 kDa
species in this sample. Fundamentally, the above-
mentioned methodologies cannot distinguish between
covalent and non-covalent structures.
Despite these limitations, further corroborative evi-
dence for the MS results can be gleaned from post-hoc
analysis of the Freelite® and Hevylite® assays (results
recorded in Table S1). The Hevylite® assay targets unique
conformational junctional epitopes which bridge the HC
(CH1 domain) and the LC (CL domain) of the intact immu-
noglobulin molecule. The monoclonal gamma HC,
(Figure 1A, peak A), and the 128 kDa, CH1 deficient species
(Figure 1A, peak B) were therefore unreactive with the IgG
kappa/IgG lambda antisera. This assay also confirmed the
absence of an intact IgG kappa (150 kDa) M-protein at
terminal relapse.
The Freelite® assay targets epitopes that are found in
many areas of the constant domain as well as in part of the
variable domain, all of which are exposed in the non-
covalently bound hetero-tetrameric 128 kDa species. The
large concentration of non-covalently bound LC’s are
therefore measured as ‘free’, resulting in a total ‘free’ LC
concentration which consists of a small amount of circu-
lating unbound free LC’s. This explains why only minute
amounts of Bence Jones protein (BJP) were detected in the
urine during the course of the patients’ disease. Regret-
tably, immunoglobulin gene sequencing was not possible
due to the unavailability of cellular DNA at the time of this
analysis. This limitation made the interpretation of the
mass spectrometric data more challenging and necessi-
tated the use of de novo sequencing.
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The new MS techniques outlined above and others
under development [5, 20, 21] will provide clinicians with
distinct advantages over the current gel and capillary
based electrophoreticmethods for patients presentingwith
paraproteinaemia. These include increased resolution,
improved turnaround time [22] and the ability to accurately
stratify therapeutic responses in the setting of monoclonal
antibody treatment when there is co-migration with the
patients’ endogenous IgG kappa M-protein [1, 23]. They
also will provide a greater understanding of the patho-
genesis of MMwhich may help to stratify patients into new
categories and potentially guide future personalized
treatment modalities [24]. In addition, native MS and
middle-down de novo sequencing provide distinctive
insight into novel protein structures and sequences that is
complementary to more traditional MS approaches.
Next generation technologies are already making an
impact in various ways at the cellular, proteomic, and
molecular level. This has resulted in the superior detection
of small numbers of malignant plasma cells, leading to
enhanced detection of MRD following treatment, or early
relapse. Dysregulation of protein production, the pathways
involved, and changes in clonal architecture can now be
identified, all combining to give critical insight into the
biology of MM development, disease progression and
treatment responses with associated development of drug
resistance [25, 26]. In summary, ourwork has demonstrated
the unique ability of next-generation technologies such as
native/top-downMS, and IP-IFE, to shed light on otherwise
elusive non-canonical monoclonal immunoproteins. As
with many next generation technologies, those reported in
thismanuscript are complex, and at present are beyond the
capabilities of health care laboratories other than those at
the leading edge of translational research. However, it can
be anticipated that further standardization and refinement
of methodologies and instrumentation will make such an
approach more accessible, helping to inform its clinical
utility in diagnosis, risk stratification, treatment strategies,
and detection of MRD and/or early relapse. We would
therefore recommend their utilization for the identification
and characterization of truncated immunoglobulin HCs,
and when the evaluation of immunochemical and elec-
trophoretic data is inexplicable or ambiguous in the clin-
ical setting of a PCD.
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